Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Berman

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Plos One|November 25, 2015
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaAlexander S Baras, Nilay Gandhi, Enrico Munari, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.
Journal of Personalized Medicine|July 31, 2015
Prioritizing Approaches to Engage Community Members and Build Trust in Biobanks: A Survey of Attitudes and Opinions of Adults within Outpatient Practices at the University of MarylandCasey Lynnette Overby, Kristin A Maloney, Tameka DeShawn Alestock, et al.
Plos One|August 1, 2015
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaAlexander S Baras, Nilay Gandhi, Enrico Munari, et al.
Histopathology|May 19, 2018
Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapyFadi Brimo, Michelle R Downes, Tamara Jamaspishvili, et al.
European Urology|November 12, 2019
Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-upLaurence Klotz, Greg Pond, Andrew Loblaw, et al.
The Journal of Molecular Diagnostics : JMD|August 9, 2020
Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue SamplesWalead Ebrahimizadeh, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
British Journal of Haematology|May 4, 2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 studyPaul G Richardson, Asher A Chanan-Khan, Sagar Lonial, et al.
Journal of Translational Medicine|November 30, 2011
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanomaOmid Hamid, Henrik Schmidt, Aviram Nissan, et al.
Plos One|November 25, 2015
Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaAlexander S Baras, Nilay Gandhi, Enrico Munari, et al.
Cancer Immunology, Immunotherapy : CII|December 8, 2011
An immune-active tumor microenvironment favors clinical response to ipilimumabRui-Ru Ji, Scott D Chasalow, Lisu Wang, et al.
Journal of Personalized Medicine|July 31, 2015
Prioritizing Approaches to Engage Community Members and Build Trust in Biobanks: A Survey of Attitudes and Opinions of Adults within Outpatient Practices at the University of MarylandCasey Lynnette Overby, Kristin A Maloney, Tameka DeShawn Alestock, et al.
Plos One|August 1, 2015
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaAlexander S Baras, Nilay Gandhi, Enrico Munari, et al.
Histopathology|May 19, 2018
Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapyFadi Brimo, Michelle R Downes, Tamara Jamaspishvili, et al.
European Urology|November 12, 2019
Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-upLaurence Klotz, Greg Pond, Andrew Loblaw, et al.
The Journal of Molecular Diagnostics : JMD|August 9, 2020
Design and Development of a Fully Synthetic Multiplex Ligation-Dependent Probe Amplification-Based Probe Mix for Detection of Copy Number Alterations in Prostate Cancer Formalin-Fixed, Paraffin-Embedded Tissue SamplesWalead Ebrahimizadeh, Karl-Philippe Guérard, Shaghayegh Rouzbeh, et al.
Pageof 6